Ibuprofen Sodium Tension Headache Study
Study Overview
Status
Status
Conditions
Conditions
Intervention / Treatment
Intervention / Treatment
Study Type
Study Type
Enrollment (Actual)
Enrollment
Phase
Phase
- Phase 3
Contacts and Locations
Study Locations
-
-
Pennsylvania
-
Philadelphia, Pennsylvania, United States, 19145
- Pfizer Investigational Site
-
-
Participation Criteria
Eligibility Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Description
Inclusion Criteria:
- Males and females at least 18 years to 65 years of age
- A diagnosis of an episodic tension-type headache, as defined by the International Headache Society
Exclusion Criteria:
- Pregnancy or breast-feeding
- Alcohol or substance abuse
- Any serious medical or psychiatric disorder
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: Randomized
- Interventional Model: Parallel Assignment
- Masking: Quadruple
Number of Arms
Arms and Interventions
Participant Group / ArmParticipant Group / Arm |
Intervention / TreatmentIntervention / Treatment |
|---|---|
|
Experimental: Treatment A
|
Single-dose of ibuprofen sodium tablets (equal to 400 mg ibuprofen)
|
|
Active Comparator: Treatment B
|
Single-dose of standard ibuprofen tablets (400mg)
|
|
Placebo Comparator: Treatment C
|
Single-dose of placebo
|
What is the study measuring?
Primary Outcome Measures
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
Time-weighted Sum of Pain Relief Rating and Pain Intensity Difference From 0-3 Hours (SPRID 0-3) for Ibuprofen Sodium Versus Placebo Tablet
Time Frame: 0-3 Hours
|
SPRID:time-weighted sum of pain relief rating combined with pain intensity difference (PRID) over 3 hours.
SPRID score range:-3 (worst) to 21 (best) for SPRID 0-3.
PRID: sum of pain intensity differences (PID) and pain relief rating(PRR) at each time point.
PRID score range: -1=worst to 7=best.
PID: baseline pain severity score minus pain severity score at a given time point (score range 0=none to 3=severe; baseline score range 2=moderately severe to 3=severe).
Total score range for PID: -1(worst) to 3 (best).
PRR:assessed on 5-point pain relief rating scale (0=No relief to 4=Complete relief).
|
0-3 Hours
|
|
Time to Onset of Meaningful Relief for Ibuprofen Sodium Versus Ibuprofen (Motrin IB) Tablet
Time Frame: 0 to 3 hours
|
Participants evaluated the time to meaningful relief by stopping a second stopwatch labeled 'meaningful relief' at the moment the participant first began to experience meaningful relief.
It was also considered achieved if the participant stated "meaningful relief" at the time the first stopwatch was depressed.
Stopwatch was active up to 3 hours after dosing or until stopped by the participant, or rescue medication was administered.
|
0 to 3 hours
|
Secondary Outcome Measures
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
Time to Onset of Meaningful Relief: Remaining Comparisons
Time Frame: 0 to 3 hours
|
Participants evaluated the time to meaningful relief by stopping a second stopwatch labeled 'meaningful relief' at the moment the participant first began to experience meaningful relief.
It was also considered achieved if the participant stated "meaningful relief" at the time the first stopwatch was depressed.
Stopwatch was active up to 3 hours after dosing or until stopped by the participant, or rescue medication was administered.
|
0 to 3 hours
|
|
Time to Confirmed First Perceptible Relief
Time Frame: 0 to 3 hours
|
Participants evaluated the time to first perceptible relief by stopping a stopwatch labeled 'first perceptible relief' at the moment the participant first began to experience any relief.
Stopwatch was active up to 3 hours after dosing or until stopped by the participant, or rescue medication was administered.
First perceptible relief was considered confirmed by meaningful relief if the participant achieved both "first perceptible" and "meaningful" relief by either depressing the second stopwatch or by indicating that his/her "first perceptible" relief was also "meaningful".
|
0 to 3 hours
|
|
Pain Relief Rating (PRR)
Time Frame: 1, 2 & 3 hours post-dose
|
PRR was assessed on a 5-point categorical pain relief rating scale wherein 0=No relief to 4=Complete relief.
|
1, 2 & 3 hours post-dose
|
|
Pain Intensity Difference (PID)
Time Frame: 1, 2 & 3 hours post-dose
|
PID was derived by subtracting the pain severity score at a given post-dosing time point [pain severity score range 0 (none) to 3 (severe)] from the baseline score [Baseline pain severity score range 2 (moderately severe) to 3 (severe)].
Total possible score range for PID: -1 (worst) to 3 (best).
|
1, 2 & 3 hours post-dose
|
|
Sum of Pain Relief Rating and Pain Intensity Difference (PRID)
Time Frame: 1, 2 & 3 hours post-dose
|
PRID was sum of PID and PRR at each post-dosing time point.
The overall possible score range, for PRID was -1 (worst) to 7 (best).
PID was derived by subtracting the pain severity score at a given post-dosing time point [pain severity score range 0 (none) to 3 (severe)] from the baseline score [Baseline pain severity score range 2 (moderately severe) to 3 (severe)].
Total possible score range for PID: -1 (worst) to 3 (best).
PRR was assessed on 5-point categorical pain relief rating scale (0=No relief to 4=Complete relief).
|
1, 2 & 3 hours post-dose
|
|
Time-weighted Sum of Pain Intensity Difference (SPID)
Time Frame: 0 to 2, 0 to 3 hours
|
SPID: time-weighted sum of PID over 2 and 3 hours.
SPID score range was -2(worst) to 6 (best) for SPID 0-2 and -3 (worst) to 9 (best) for SPID 0-3.
PID: baseline pain severity score minus pain severity score at a given time point (score range 0=none to 3=severe; baseline score range 2=moderately severe to 3=severe).
Total score range for PID: -1(worst) to 3 (best).
|
0 to 2, 0 to 3 hours
|
|
Time-weighted Sum of Pain Relief Rating (TOTPAR)
Time Frame: 0 to 2, 0 to 3 hours
|
TOTPAR: time-weighted sum of PRR over 2 and 3 hours.
TOTPAR score range was 0 (worst) to 8 (best) for TOTPAR 0-2 and 0 (worst) to 12 (best) for TOTPAR 0-3.
PRR was assessed on a 5-point categorical pain relief rating scale wherein 0=No relief to 4=Complete relief.
|
0 to 2, 0 to 3 hours
|
|
Time-weighted Sum of Pain Relief Rating and Pain Intensity Difference (SPRID)
Time Frame: 0 to 2, 0 to 3 hours
|
SPRID: time-weighted sum of PRID over 2 and 3 hours.
SPRID score range was -2(worst) to 14(best) for SPRID 0-2 and -3 (worst) to 21 (best) for SPRID 0-3.
PRID: sum of PID and PRR at each time point.
Total score range for PRID: -1=worst to 7=best.
PID: baseline pain severity score minus pain severity score at a given time point (score range 0=none to 3=severe; baseline score range 2=moderately severe to 3=severe).
Total score range for PID: -1(worst) to 3(best), PRR: assessed on 5-point pain relief rating scale (0=No relief to 4=Complete relief).
|
0 to 2, 0 to 3 hours
|
|
Cumulative Percentage of Participants With Meaningful Relief
Time Frame: 0.5, 1, 2, 3 hours
|
Percentage of participants with meaningful relief evaluated by stopping a second stopwatch labeled 'meaningful relief' at the moment the participant first began to experience meaningful relief.
It was also considered achieved if the participant stated "meaningful relief" at the time the first stopwatch was depressed.
Stopwatch was active up to 3 hours after dosing or until stopped by the participant, or rescue medication was administered.
|
0.5, 1, 2, 3 hours
|
|
Cumulative Percentage of Participants With First Perceptible Relief
Time Frame: 0.5, 1, 2, 3 hours
|
Percentage of participants with first perceptible relief evaluated by stopping a stopwatch labeled 'first perceptible relief' at the moment the participant first began to experience any relief.
Stopwatch was active up to 3 hours after dosing or until stopped by the participant, or rescue medication was administered.
First perceptible relief was considered confirmed by meaningful relief if the participant achieved both "first perceptible" and "meaningful" relief by either depressing the second stopwatch or by indicating that his/her "first perceptible" relief was also "meaningful".
|
0.5, 1, 2, 3 hours
|
|
Duration of Relief
Time Frame: 0 to 3 hours
|
Median participant time for dropping out of the study due to lack of efficacy or receipt of rescue medication, whichever came first.
|
0 to 3 hours
|
|
Cumulative Percentage of Participants With Treatment Failure
Time Frame: 1, 2, 3 hours post-dose
|
Percentage of participants who withdrew from the study due to lack of efficacy or received rescue medication.
|
1, 2, 3 hours post-dose
|
|
Cumulative Percentage of Participants With Complete Relief
Time Frame: 1, 2, & 3 hours post-dose
|
Complete relief was defined as a PRR of 4. PRR was assessed on a 5-point categorical pain relief rating scale where 0=No relief to 4=Complete relief
|
1, 2, & 3 hours post-dose
|
Collaborators and Investigators
Sponsor
Sponsor
Publications and helpful links
General Publications
- Packman E, Leyva R, Kellstein D. Onset of analgesia with ibuprofen sodium in tension-type headache: a randomized trial. J Pharm Health Care Sci. 2015 Apr 2;1:13. doi: 10.1186/s40780-015-0012-9. eCollection 2015.
- Jayawardena S, Leyva R, Kellstein D. Safety of a novel formulation of ibuprofen sodium compared with standard ibuprofen and placebo. Postgrad Med. 2015 Jan;127(1):33-7. doi: 10.1080/00325481.2015.993268. Epub 2014 Dec 15.
Study record dates
Study Major Dates
Study Start
Study Start
Primary Completion (Actual)
Primary Completion
Study Completion (Actual)
Study Completion
Study Registration Dates
First Submitted
First Submitted
First Submitted That Met QC Criteria
First Submitted That Met QC Criteria
First Posted (Estimate)
First Posted
Study Record Updates
Last Update Posted (Estimate)
Last Update Posted
Last Update Submitted That Met QC Criteria
Last Update Submitted That Met QC Criteria
Last Verified
Last Verified
More Information
Terms related to this study
Keywords
Additional Relevant MeSH Terms
- Brain Diseases
- Central Nervous System Diseases
- Nervous System Diseases
- Pain
- Neurologic Manifestations
- Headache Disorders, Primary
- Headache Disorders
- Headache
- Tension-Type Headache
- Physiological Effects of Drugs
- Molecular Mechanisms of Pharmacological Action
- Peripheral Nervous System Agents
- Enzyme Inhibitors
- Analgesics
- Sensory System Agents
- Anti-Inflammatory Agents, Non-Steroidal
- Analgesics, Non-Narcotic
- Anti-Inflammatory Agents
- Antirheumatic Agents
- Cyclooxygenase Inhibitors
- Ibuprofen
Other Study ID Numbers
Other Study ID Numbers
- AH-11-16
- B3411007
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.